Biological and Pharmaceutical Biotechnology, Master of Science
Improving the Way We Live
From new medications to genetics, the pharmaceutical and biotechnology industries harness biological processes to meet our society’s commercial and health-related needs.
- Prepare for an exciting career in a vital, fast-growing field.
- Gain the scientific and laboratory skills to conduct research that can improve lives.
- Develop the administrative skills to advance in the biotech industry.
Zhe-Sheng Chen, M.D., Ph.D.
Director, Institute for Biotechnology
Professor of Pharmaceutical Sciences
College of Pharmacy & Health Sciences
St. John's University
Dr. Somnath Pal
Associate Director, Institute for Biotechnology
Professor of Pharmacy Administration
College of Pharmacy & Health Sciences
St. John's University
Please see a list of our Pharmaceutical Sciences faculty.
The program gives students a thorough understanding of the scientific theory and advanced laboratory research techniques vital to success in pharmaceutical and biotechnology industries. Students also receive valuable internship experience in this revolutionary field.
Students complete a 33 credit, interdisciplinary program with courses offered by the Department of Biological Sciences, Chemistry, Pharmaceutical Sciences, and Pharmacy and Administrative Sciences—15 credits in a pharmaceutical biotechnology “core,” 15 credits in elective courses and a three-credit Internship in biotechnology at an approved site. Students must maintain a grade point average of at least 3.0 in the program. All courses are given in the evening.
Applicants need to submit the following items with their admission application:
- B.S. or B.A. or equivalent with a major in life sciences or physical sciences
- Official transcripts reflecting a minimum GPA of 3.0 on a 4.0 scale
- Satisfactory GRE scores
- A minimum of two letters of reference
- Foreign-born students who have not received a U.S. degree are required to present evidence of proficiency in English such as the TOEFL test
The outlined curriculum provides a strong conceptual foundation upon which students can build the practical skills to excel in this exciting field. Students must complete a minimum of 33 credits, 18 of which are satisfied by the completion of the required core courses, including an off-campus internship that students take preferably in their final semester or after they have completed a minimum of 21 credits with a 3.0 index.
Regular and prompt attendance is expected of all students. Absence from class does not excuse a student from work missed. Individual faculty member have discretionary power to determine whether a student who has missed an announced test is to be given a make-up exam. This policy does not apply to final examinations which are administered by the Dean’s office at an appointed time.
There are no fellowships or graduate assistantships offered for this degree program.
Students must maintain a GPA of 3.0. A student with a GPA of less than 3.0 is placed on academic probation and has one semester to correct the deficiency. If uncorrected after one semester, the student will be dismissed from the program. Students may appeal dismissal to the Director of the Institute for Biotechnology who acts as Dean for the program.
Transfer of Credit
A student may transfer up to six (6) graduate credits from another fully accredited institution of higher learning to substitute for courses in the curriculum. The student should present a syllabus of the course for which he or she is requesting credit and an official transcript for the College or University to the Director of the Institute for Biotechnology. The syllabus will be evaluated by the chair of the department offering the corresponding course in the curriculum. If it is deemed to be the equivalent the student will receive transfer credit for the course.
Office of Graduate Admission
Pharmaceutical biotechnology draws upon such disciplines as microbiology, biochemistry and molecular and cellular biology. The biopharmaceutical industry employed 55,446 people and was responsible for a total of 130,464 jobs in New York State in 2009. The industry generated $29.1 billion in total output of which $16 billion was generated from direct employment. In 2012, New York State will invest some $50 million in the biosciences through the Regional Economic Development Council Initiative. These investments will enable further growth in a field that supports some 250,000 direct, indirect and induced jobs, and contributes over $32 billion a year to the state’s economic output, according to an analysis by the New York Biotechnology Association (NYBA).
Companies and agencies that specialize in pharmaceutical biotechnology seek skilled professionals to meet the industry’s scientific and administrative demands. Career opportunities abound in clinical labs, information technology, large pharmaceuticals, research labs and even small start-ups. You can prepare for these careers through the Master of Science Degree Program in Biological and Pharmaceutical Biotechnology at St. John’s University. This interdisciplinary program is a joint effort of the College of Pharmacy and Health Sciences and St. John’s College of Liberal Arts and Sciences — two acclaimed divisions of St. John’s University.
“The Professional Science Master's (PSM) is an innovative, new graduate degree designed to allow students to pursue advanced training in science or mathematics, while simultaneously developing workplace skills highly valued by employers. PSM programs consist of two years of academic training in an emerging or interdisciplinary area, along with a professional component that may include internships and "cross-training" in workplace skills, such as business, communications, and regulatory affairs. All have been developed in concert with employers and are designed to dovetail into present and future professional career opportunities.”
The M.S. in Biological and Pharmaceutical Biotechnology was developed as a Professional Science Master’s degree program with funding in the form two grants from the Sloan Foundation through the Council of Graduate Schools in 2003. The degree program was approved by the New York State Department of Education in May, 2006 and the first class was admitted in January, 2007.
“The National Professional Science Master's Association (NPSMA) is a collaborative of Professional Science Master's (PSM) degree program directors, faculty, administrators, alumni, and students that supports PSM degree initiatives. It engages businesses, industries, nonprofit organizations, government agencies, and trade associations in the development of PSM degree programs and with internship and job placement for PSM degree students and graduates.”
St. John’s University Institute for Biotechnology, its students and alumni are members of the National Professional Science Master’s Association. Students and alumni benefit from networking with their counterparts in other Professional Science Master’s programs around the country. The NPSMA also facilitates internship and job placement for its members.
“The New York Biotechnology Association (NYBA) is a not-for-profit trade association dedicated to the development and growth of New York State based biotechnology related industries and institutions, and to strengthening the competitiveness of New York State as a premier global location for biotechnology/biomedical research, education and industry.”
St. John’s University Institute for Biotechnology has been a member of NYBA since 2003 and has been a sponsor of the NYBA Annual Meeting since that time. At the 18th Annual meeting in April 2009, Dr. Diana Bartelt, Director of the Institute, chaired a panel entitled “Employee Development Program Alliances with Academia: The Hidden Benefits.”
“TheLong Island Life Sciences Initiative(LILSI) has as its mission to attract, retain and develop life sciences companies in the pharmaceutical, biotechnology, medical device, nutriceutical and personal care sectors on Long Island by providing business development, strategic networking, and educational opportunities to enhance corporate competitiveness, productivity, efficiency and profitability.”
St. John’s Institute for Biotechnology has been a sponsor of the Long Island Life Sciences Initiative Annual Summit Meetings since 2003. Students in the M.S. in Biological and Pharmaceutical Biotechnology degree program have served as volunteers at the meetings and participated in job fairs.
Advisory Board Members
Jason Alter, Ph.D.
Vice President of Marketing for Aureon Laboratories
Dr. Alter graduated from Alfred University with a B.A. in Biology and History. Subsequently he earned a M.S. degree in Microbiology from Texas A&M University and his Ph.D. in Molecular Biology from Binghamton University. Dr. Alter did a postdoctoral fellowship at Schering Plough Pharmaceuticals examining the cellular location of fibronectin and collagen 01 (IV) messenger RNAs during intimal lesion development in a balloon angioplasty model of vascular smooth muscle cell proliferation. Dr. Alter has worked in a number of marketing roles for both traditional and non-traditional life science companies (e.g. IBM). Dr. Alter joined IBM's newly-formed Life Sciences Division as a Marketing Manager and was responsible for many of the initial outbound marketing activities of this business unit. Subsequently, as Manager of Program Marketing, he and his team were responsible for all outbound marketing for the IBM Healthcare and Life Sciences team.
John D. Haley, Ph.D.
Senior Research Director, Translational Research OSI Pharmaceuticals, Inc.
Dr. Haley has over thirty years of experience in biochemical research in the fields of endocrinology, oncology, signal transduction and pharmacology, in which he has published over 50 manuscripts. Dr. Haley obtained B.Sc. cum laude in Chemistry from Tufts University, Medford, MA and a Ph. D. in Molecular Endocrinology from the Howard Florey Institute for Experimental Physiology and Medicine, Melbourne University, Australia. He served as a Research Fellow at the Imperial Cancer Research Fund (London) and at the Ludwig Institute for Cancer Research (London). He currently holds the position of Senior Research Director, Translational Research at OSI Pharmaceuticals, and his group is focused on drug target pathway identification, validation and biomarker discovery through a scientific understanding of epithelial-mesenchymal transition and cancer recurrence.
Joseph Scaduto, M.S., M.B.A.
Assistant Director of Business Development Center for Biotechnology (CFB), State University of New York at Stony Brook
Mr. Scaduto is the founding Executive Director of the Long Island Life Sciences Initiative (LILSI). He has accumulated almost 10 years of experience providing business development expertise, strategic planning services and technology commercialization guidance to emerging and expanding bioscience companies on Long Island and throughout New York State. Mr. Scaduto is primarily responsible for corporate outreach, industry relations and government affairs activities on behalf of the CFB. He leads efforts to plan and execute the annual Life Sciences Industry Summit, while administering several programs meant to facilitate industry-academic interactions, technology transfer and new company formation, including BioPartnering Meetings, BioStrategy Sessions and the Technology Commercialization Clinic (TCC). Mr. Scaduto serves on the Tenant Selection and Review Committee of the Long Island High Technology Incubator (UHTI), the Stony Brook University Software Incubator, and the Stony Brook University Incubator at Calverton. Prior to joining the CFB, Mr. Scaduto held a variety of laboratory research and technology management positions at Stony Brook University, Brookhaven National Laboratory, Binghamton University, Mount Sinai Graduate School of Biological Sciences, BioLife Solutions, Inc. and The Collaborative Group, Ltd.
Mark Sleeman, Ph.D.
Dr. Sleeman is currently the Head of Metabolic Research at Regeneron Pharmaceuticals in Tarrytown, New York. For the past two decades he has been interested in the interplay between insulin resistance and obesity, in particular the molecular mechanisms behind the regulation food intake and body weight. Recently, his published research has focused on the role that gut hormones such as ghrelin and PYY play in signaling to a number of brain regions to modulate metabolic events. To that end he and his colleagues have generated a number of genetically modified animals to study these phenotypes. Mark Sleeman was a recipient of a Juveniles Diabetes and Ruth Kirschstein Endocrine Fellowship at the University of Massachusetts in the laboratory of Dr Michael P. Czech where he studied mechanisms insulin-resistance/signaling. He received his Ph.D. from Monash University after graduating from The University of Melbourne, Australia. He has published numerous papers on Type 2 Diabetes and Obesity in journals such as Nature Medicine, Nature Genetics, PNAS, Journal of Biological Chemistry and Diabetes, is a member of numerous professional societies in US and holds the academic appointment of Adjunct Professor in the Comparative Medicine Department at Yale University School of Medicine.
Linda Strausbaugh, Ph.D.
Professor of Genetics and Genomics
Director, Center for Applied Genetics and Technology
Director, Professional Science Master's Degree in Applied Genomics
Chair of the Council of Graduate Schools PSM Advisory Board
Dr. Strausbaugh recieved her B.S. from Wright State University and her Ph.D. from Wesleyan University. Dr. Strausbaugh joined the faculty at the University of Connecticut in 1980. Her research interests are in DNA identity typing for forensic and ancestry applications, and in genome evolution. She designed and obtained funding to create UConn's Center for Applied Genetics and Technology, a state-of-the-art facility supporting integrated genomics research and education. Multimillion dollar awards support her DNA typing research for crime lab improvement, and she leads collaborations with several corporate partners to develop new DNA identification methods. Professor Strausbaugh is recognized locally and nationally as an education innovator. She has developed and taught a number of genetics courses, including all three of the genetics courses for undergraduates at the University of Connecticut. Her genetics class was named a "Best on Campus" in the Boston Globe. Dr. Strausbaugh played key roles in the creation and teaching of courses on Forensic Applications of DNA Science, Experiments in DNA Identification, and Responsible Conduct of Research. She was named a 1997 Teaching Fellow of theUniversity of Connecticut, and is a 2010 Top Nominee for the national Robert Foster Cherry Award for Great Teaching. She is active in local and national diversity initiatives and was named a 1998 NEBHE Faculty Mentor of the Year. Dr. Strausbaugh has served as mentor and research supervisor to dozens of undergraduate and graduate students. She conceived of and directs the Professional Science Masters in Applied Genomics. PSM degrees are designed to address the national shortage of science-trained professionals, and Dr. Strausbaugh works routinely with the Connecticut Business and Industry Association and several companies.
Edward Tamer, Ph.D.
Senior Manager, Head of Lead Optimization Group
CNS Therapeutic Domain
Sanofi-Aventis US, Inc.
Dr. Tamer graduated with a PhD in Biochemistry in January 1985 from University Paul-Sabatier-School of Pharmacy in Toulouse, France. Immediately thereafter he began a career in the pharmaceutical industry by joining UCB-Pharma in Belgium. From 1989-1999, and while still employed by UCB Pharma, he moved to the US where he took on the responsibility of coordinating an extensive collaboration project between UCB-Pharma and the Department of Pharmacology and Experimental Therapeutics at Loyola University Stritch School of Medicine in Illinois. This included a Research Faculty position with participation in teaching in the pharmacology graduate program in the department. Next he joined the Vascular Biology Group at Cornell University Weil Medical College in New York from 1999-2002. He then moved to the Orentreich Foundation for the Advancement of Science in Cold Spring, NY where led the Cell Biology group from 2002 – 2005. Then he returned to industry and joined Sanofi-Aventis, where he held a Senior Manager position heading the lead Optimization group in the central nervous system therapeutic domain. Currently he holds a senior position in the “Expertis platform of Biology of aging” in the newly created therapeutic strategic unit of Aging at Sanofi-Aventis. During his professional career, Dr. Tamer’s research activity continued to focus on understanding the mechanisms of diseases with emphasis on drug discovery, applying biochemical , molecular and pharmacological approaches and techniques.
Daniel B. Yarosh,Ph.D.
Senior Vice President, Basic Science Research Estee Lauder
Dr. Yarosh, is Senior Vice President, Basic Science Research, and is responsible for worldwide basic research of the Estee Lauder companies. Until 2008, he was President and Chairman of the Board, AGI Dermatics, located in Freeport, Long Island, New York. Dr. Yarosh received his BA degree in Biology from Macalester College, St. Paul, Minnesota, in 1976, and his Doctorate in Molecular Biology from the University of Arizona College of Medicine, Tucson, Arizona, in 1978. He served as a National Science Foundation Fellow at Brookhaven National Laboratory, Upton, New York, and then a Staff Fellow and Cancer Expert at the National Cancer Institute of the National Institutes of Health, Bethesda, Maryland. In 1985, Dr. Yarosh founded AGI Dermatics, with an emphasis on the commercial application of DNA repair. He is the inventor of Dimericine® (T4N5 liposome lotion), which is a liposomal DNA repair enzyme for the prevention of skin cancer. AGI Dermatics is also an ingredient supplier to many major worldwide cosmetic and personal care companies. In 2006 the company launched its own Remergent® brand of skincare products, including sunscreens and prescription drugs. In 2008, AGI Dermatics was acquired by Estee Lauder Inc. Dr. Yarosh is the author of more than 100 scientific papers and two dozen patents, and serves on the Board of the Photomedicine Society. His book The New Science of Perfect Skin, about skincare technology in the cosmetic marketplace, was published by Random House in May 2008.